Contiguous squamous proliferations in syringocystadenoma papilliferum: A retrospective study of 14 cases
How to cite this article: Aggarwal D, Chatterjee D, Keshavamurthy V, Chhikara K, Saikia UN, Radotra BD, et al. Contiguous squamous proliferations in syringocystadenoma papilliferum: A retrospective study of 14 cases. Indian J Dermatol Venereol Leprol, doi: 10.25259/IJDVL_845_20
Syringocystadenoma papilliferum is a benign adnexal neoplasm. Contiguous squamous proliferation has been rarely described in syringocystadenoma papilliferum.
This study aimed to evaluate the spectrum and pathogenesis of contiguous squamous proliferation in syringocystadenoma papilliferum.
Materials and Methods:
All cases of syringocystadenoma papilliferum diagnosed over the past 12 years were screened for contiguous squamous proliferation. Cases with associated nevus sebaceous were excluded from the study. Immunohistochemistry for GATA3, CK7, BRAFV600E and p16 was performed. PCR for human papilloma virus, type 16 and 18, was carried out.
Of a total of 30 cases, 14 cases showed associated contiguous squamous proliferation which included four cases of verrucous hyperplasia, six cases with papillomatosis, two cases with mild squamous hyperplasia and one case each of Bowen’s disease and squamous cell carcinoma. In the cases with non-neoplastic contiguous squamous proliferations, the squamous component did not express CK7 or GATA3. However, the squamous component of premalignant and malignant lesions expressed CK7 and GATA3 concordant with the adenomatous component. BRAF was positive in adenomatous component in five cases while the contiguous squamous proliferation component was negative for BRAF in all but one case. p16 was negative in both components of all cases and PCR for human papilloma virus was negative in all cases.
Due to the rarity of disease, the sample size of our study was relatively small with two cases in the 2nd group, that is, syringocystadenoma papilliferum with malignant contiguous squamous proliferation. Detailed molecular studies such as gene sequencing were not performed.
Syringocystadenoma papilliferum with contiguous squamous proliferation is underreported, and most commonly displays verrucous hyperplasia. The premalignant and malignant contiguous squamous proliferations likely arise from syringocystadenoma papilliferum while the hyperplastic contiguous squamous proliferations likely arise from the adjacent epidermis. Relationship with high-risk human papilloma virus is unlikely. However, further molecular analysis of larger number of cases is required to establish the pathogenesis.
Plain Language Summary
Syringocystadenoma papilliferum is a relatively uncommon skin disease. Sometimes, small growths occur alongside the tumour, which are called contiguous squamous proliferations, whose exact nature is unknown. The latter can be benign or cancerous. The authors aimed to study the origin of contiguous squamous proliferations in syringocystadenoma papilliferum. They studied 30 cases of the latter, of which 14 had contiguous squamous proliferations. Among these 14 cases, two had cancerous squamous proliferations while the remaining 12 were benign. The authors studied the expression of certain proteins in the tissue of these cases. They found that cancerous contiguous squamous proliferations have protein expression similar to that of syringocystadenoma papilliferum, while the benign ones have different protein expressions. So, the authors concluded that benign contiguous squamous proliferations seem to originate from the adjacent skin lining while the cancerous ones are likely to arise from syringocystadenoma papilliferum.
Syringocystadenoma papilliferum is a benign adnexal neoplasm derived from pluripotent cells.1 Rarely, contiguous squamous proliferations appear in syringocystadenoma papilliferum. Contiguous squamous proliferations are squamous proliferations which appear adjacent to syringocystadenoma papilliferum.2 The exact pathogenesis of contiguous squamous proliferations in syringocystadenoma papilliferum is unclear and this study is aimed to identify the morphological spectrum and frequency of contiguous squamous proliferation in syringocystadenoma papilliferum and to explore its pathogenesis.
Materials and Methods
The institutional histopathology database at Postgraduate Institute of Medical Education and Research, Chandigarh, India, was searched to identify all cases diagnosed as syringocystadenoma papilliferum over the past 12 years, that is, from January 2007 to July 2019. Cases with associated nevus sebaceous or those with insufficient tissue in the block were excluded from the study.
Demographic data, location and size of lesion were obtained from the requisition forms. The slides and blocks were retrieved for all cases. All cases were reviewed by three pathologists and were subdivided into two categories: cases with contiguous squamous proliferation and those without.
Immunohistochemistry for cytokeratin 7 (CK7, Dako, 1:100), GATA3 (Cell Marque, 1:300), BRAF (BRAF v600e VE1 clone, Ventana, ready to use) and p16 (Ventana, ready to use) was performed using Ventana autostainer in all cases of syringocystadenoma papilliferum with contiguous squamous proliferation. For BRAF, granular cytoplasmic positivity in >10% cells was considered positive.3 Immunohistochemistry was assessed adenomatous component of syringocystadenoma papilliferum and in the contiguous squamous proliferation separately. DNA PCR (polymerase chain reaction) for human papilloma virus 16/18 was performed in all cases with contiguous squamous proliferation, using formalin fixed paraffin-embedded tissue.
The tissue was deparaffinized using xylene and ethanol in decreasing concentration. Genomic DNA was extracted using commercially available kit (Qiagen, Germany) as per manufacturer’s protocol. Later, PCR was performed for the presence of human papilloma virus 16 and 18 by targeting the regulatory gene (271 bp) and E6 region (100 bp), respectively, using gene specific primers.4
A total of 36 cases of syringocystadenoma papilliferum were identified, of which six were excluded as they had an associated nevus sebaceous. Among the remaining 30 cases, 14 cases (46.7%) had an associated contiguous squamous proliferation.
The mean age of patients with contiguous squamous proliferation (n = 14) was 50 ± 23 years with no gender predilection. Most common location was scalp (n = 8; 57.2%) followed by forehead, cheek and pre-auricular region (two each; 14.3%). The mean size of lesion was 13.1 ± 11.7 mm. The most common clinical presentation was skin colored to erythematous warty papules [Figures 1a and Table 1]. In patients of syringocystadenoma papilliferum without contiguous squamous proliferation (n = 16), mean age was 38.8 ± 12.6 years with a male: female ratio of 1:1.7. Scalp was the most common site (n = 12; 75%), followed by forehead, cheek, eyelid and neck (one each; 6.3%). The average size of lesion was 10.3 ± 11.6 mm. There was no significant difference in these two groups in terms of age, sex ratio, location or size of the lesion.
|Case no.||Age (years)||Gender||Size of lesion (mm)||Site||Clinical presentation||Contiguous squamous proliferations|
|1||32||Male||12||Scalp||Well-defined nodule||Mild squamous hyperplasia|
|2||56||Female||50||Forehead||Ulceroproliferative growth||Squamous cell carcinoma|
|3||60||Male||15||Pre-auricular||Ulceroproliferative growth||Bowen’s disease|
|4||61||Male||8||Scalp||Ulceroproliferative lesion||Verrucous hyperplasia|
|5||27||Male||15||Helix||Verrucous nodular lesion with aggregated keratotic papules||Papillomatosis|
|6||27||Female||5||Scalp||Nodular lesion||Mild squamous hyperplasia|
|7||11||Female||10||Scalp||Verrucous skin colored
|8||47||Female||15||Scalp||Ulcerated nodule with patch of hair loss||Papillomatosis with koilocytosis|
|10||25||Male||4||Scalp||Solitary nodular lesion||Papillomatosis with koilocytosis|
|11||70||Male||20||Scalp||Verrucous skin colored
|12||86||Female||15||Pre-auricular||Verrucous raised lesion||Verrucous hyperplasia|
|14||66||Male||10||Forehead||Single well-defined nodule||Papillomatosis|
Based on histological examination, contiguous squamous proliferations were divided into two groups, Group 1 (n = 12) included hyperplastic or reactive conditions and Group 2 (n = 2) included pre-neoplastic and neoplastic conditions. In Group 1, papillomatosis was the most common finding (6/14, 42.9%) followed by verrucous hyperplasia (4/14, 28.6%) and mild squamous hyperplasia (2/14, 14.3%) [Figures 1b, 1c and 2]. Two out of four cases with papillomatosis showed wart-like morphology with the presence of acanthosis, hypergranulosis and koilocytic atypia. Group 2 included one (7.1%) case each of Bowen’s disease and squamous cell carcinoma [Figure 3].
On immunohistochemistry [Figures 4 and 5], adenomatous component (syringocystadenoma papilliferum) showed positivity for CK7 in all cases [Figure 4a and 5b]. Hyperplastic contiguous squamous proliferations were negative for CK7 [Figure 4a] while neoplastic contiguous squamous proliferations were positive for CK7 [Figure 5b]. GATA3 expression was variable in the adenomatous component, as indicated in Table 2. The contiguous squamous proliferation component of the case with squamous cell carcinoma was positive for GATA3 while all other contiguous squamous proliferations were negative for GATA3 [Figures 4 and 5]. Adjacent normal epidermis was negative for CK7 and GATA3 in all cases. Immunohistochemistry for p16 was negative in all cases in both the components. PCR for human papilloma virus 16/18 DNA was negative in all cases.
|Type of CSP||Number||CK7||GATA3||BRAF|
|Mild squamous hyperplasia||2||Positive (2/2)||Negative (0/2)||Positive (2/2)||Negative (0/2)||Positive (2/2)||Negative (0/2)|
|Verrucous hyperplasia||4||Positive (4/4)||Negative (0/4)||Positive (3/4)||Negative (0/4)||Positive (1/4)||Negative (0/4)|
|Papillomatosis with koilocytes||2||Positive (2/2)||Negative (0/2)||Positive (2/2)||Negative (0/2)||Positive (1/2)||Negative (0/2)|
|Papillomatosis||4||Positive (4/4)||Negative (0/4)||Positive (2/4)||Negative (0/4)||Positive (1/4)||Positive (1/4)|
|Bowen’s disease||1||Positive (1/1)||Positive (1/1)||Negative (0/1)||Negative (0/1)||Negative (0/1)||Negative (0/1)|
|Squamous cell carcinoma||1||Positive (1/1)||Positive (1/1)||Positive (1/1)||Positive (1/1)||Negative (0/1)||Negative(0/1)|
Immunohistochemistry for BRAFV600E was positive in the adenomatous (syringocystadenoma papilliferum) component in five (35.7%) cases [all with hyperplastic contiguous squamous proliferation, Figure 4c]. The contiguous squamous proliferation component showed positivity for BRAFV600E in a single case which showed papillomatosis (adenomatous component was also positive). All remaining hyperplastic and neoplastic contiguous squamous proliferations were negative for BRAF. A summary is presented in Table 2.
Syringocystadenoma papilliferum is a benign adnexal neoplasm which can either occur sporadically or within a pre-existing nevus sebaceous.2 Without background nevus sebaceous, syringocystadenoma papilliferum not uncommonly demonstrates contiguous squamous proliferations including metaplastic, hyperplastic and neoplastic proliferations.1,2,5-12 Our study aimed to identify the spectrum and frequency of contiguous squamous proliferations in syringocystadenoma papilliferum and to explore their pathogenesis.
Among 30 syringocystadenoma papilliferum cases, 14 cases (46.7%) had contiguous squamous proliferations. Friedman et al. reported a higher incidence (9/12, 75% cases) of contiguous squamous proliferations.1 Konstantinova et al. studied syringocystadenoma papilliferum of anogenital region where 10/16 cases (62.5%) had contiguous squamous proliferations.2 The clinical appearance of the lesion is unable to predict underlying contiguous squamous proliferation. The mean age of patients of syringocystadenoma papilliferum with contiguous squamous proliferation in this study was higher than patients without contiguous squamous proliferation, although this difference was not statistically significant. It is possible that longer duration of syringocystadenoma papilliferum may be associated with the development of contiguous squamous proliferation, and thus, these lesions should be excised and subjected to histological examination.
The exact pathogenesis of these contiguous squamous proliferations in syringocystadenoma papilliferum remains unclear. The role of human papilloma virus 16/18 infection has also been suggested.2,9 In this study, we found that the adenomatous component of contiguous squamous proliferations expressed CK7 and GATA3, whereas these markers were not expressed by hyperplastic contiguous squamous proliferation component. Interestingly, the neoplastic contiguous squamous proliferations showed concordant expression of CK7 and GATA3 in both adenomatous and contiguous squamous proliferation components while the normal adjacent epidermis was negative. Normal squamous epithelium and epidermis are known to express high-molecular-weight cytokeratin and not low-molecular-weight cytokeratin including CK7. Squamous cell carcinomas arising from skin or mucous membrane or Bowen’s disease are also positive for high-molecular-weight cytokeratin and negative for CK7, similar to their normal counterparts. Both neoplastic contiguous squamous proliferations in our series showed strong CK7 expression, similar to adenomatous (syringocystadenoma papilliferum) component. These findings indicate that neoplastic contiguous squamous proliferations likely arise from the adenomatous component while hyperplastic contiguous squamous proliferations possibly originate from adjacent squamous epithelium/epidermis. We could not find any similar studies in literature, to make any valid comparisons with our results. We hypothesize that syringocystadenoma papilliferum undergoes squamous metaplasia which subsequently undergoes neoplastic transformation. Which factors actually trigger this neoplastic transformation is a matter of debate.
The role of human papilloma virus 16/18 in contiguous squamous proliferations in syringocystadenoma papilliferum is disputed. A few authors have described occasional cases with human papilloma virus positivity. Konstantinova et al. reported a single case with human papilloma virus 16 positivity among ten cases showing contiguous squamous proliferation in anogenital syringocystadenoma papilliferum while none showed p16 positivity.2 Skelton et al. reported a single case of syringocystadenoma papilliferum associated with condyloma acuminatum which was positive for human papilloma virus 6/11 by in situ hybridisation.9 However, none of the four cases of syringocystadenoma papilliferum with verrucous carcinoma described by Alegría-Landa et al. showed any relation with human papilloma virus.5 We performed PCR for human papilloma virus 16/18 since this is the most common high-risk human papilloma virus in Indian scenario. However, we could not perform PCR for low-risk human papilloma virus and other high-risk human papilloma viruses. None of our cases showing contiguous squamous proliferation (including two cases which showed koilocytic atypia on morphology) tested positive for human papilloma virus 16/18 or showed p16 positivity. Our findings corroborate those of other authors and it is unlikely that high-risk human papilloma virus plays a role in the pathogenesis of contiguous squamous proliferations.
BRAFV600E expression in syringocystadenoma papilliferum has been variably reported by various authors and its role has been suggested in the pathogenesis of syringocystadenoma papilliferum. Friedman et al. reported BRAF expression in syringocystadenoma papilliferum and contiguous squamous proliferation component in seven and four out of nine cases, respectively.1 Konstantinova et al. performed BRAF mutation analysis and five of their ten cases with contiguous squamous proliferations tested positive, although they did not perform BRAF mutation analysis in syringocystadenoma papilliferum and contiguous squamous proliferation separately.2 Thus, it is not clear whether the contiguous squamous proliferation component also showed BRAF mutation. Half of the cases in a study by Alegría-Landa et al. showed BRAF immunohistochemistry positivity in both components, by immunohistochemistry and PCR.5 Five of our 14 (35.7%) cases showed BRAF expression in syringocystadenoma papilliferum component and only one case showed BRAF positivity in contiguous squamous proliferation component. Syringocystadenoma papilliferum and contiguous squamous proliferation showing BRAF expression in our study are less as compared to that reported in literature. It could be because of the 10% positivity cutoff criteria that we used in this study or due to true biological variation of the disease. It is likely that BRAF mutation plays a role in pathogenesis of syringocystadenoma papilliferum, however, our findings as well as those of other authors do not indicate its role in contiguous squamous proliferation.
Due to the rarity of the disease, our study is limited by its small size. There were only two cases with malignant contiguous squamous proliferations associated with syringocystadenoma papilliferum, hence, the pathogenetic mechanisms can only be proposed and no firm conclusions can be drawn. Detailed molecular studies such as gene sequencing were not performed in this study. Human papilloma virus testing was done only for human papilloma virus 16/18 and testing for low-risk human papilloma virus and other high-risk human papilloma virus was not done. Further studies with larger sample size would be required for exploring these mechanisms.
Contiguous squamous proliferations in syringocystadenoma papilliferum are a relatively common but under-recognized phenomenon. Our findings indicate that high-risk human papilloma virus is unlikely to play a role in the pathogenesis of contiguous squamous proliferations in syringocystadenoma papilliferum. It is likely that hyperplastic proliferations arise from the adjacent squamous epithelium as a reactive change while the adenomatous component gives rise to neoplastic proliferations, although the molecular mechanism could not be determined. However, this needs to be confirmed by larger studies with larger number of neoplastic cases. This study further reiterates that longstanding syringocystadenoma papilliferum may develop contiguous squamous proliferation, hence should be excised. In cases which are managed conservatively, close follow-up is advised.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
- Ann Clin Lab Sci. 2002;32:434-7.Verrucous carcinoma arising within syringocystadenoma papilliferum.
- [Google Scholar]
- Skinmed. 2015;13:395-7.Eruptive syringocystadenoma papilliferum, keratoacanthoma, and verruca vulgaris in a keratinocytic epidermal nevus on the leg.
- [Google Scholar]
- Indian Dermatol Online J. 2019;10:168-70.Well-differentiated squamous cell carcinoma arising in syringocystadenoma papilliferum.
- [Google Scholar]